2-Hydroxypropyl-ß-Cyclodextrin Complex with Ketotifen Fumerate for Eye Drops Preparations
Keywords:
Ketotifen Fumerate, 2-Hydroxypropyl-ß-cyclodextrin, Inclusion complex, Solubility, StabilityAbstract
Ketotifen fumerate ophthalmic solution is an antihistaminic drug. The aim of this study was to develop a novel aqueous ketotifen eye drop formulation containin ketotifen/2-Hydroxypropyl-β-cyclodextrin complex, which has the ability to enhance the solubility of the drug at the physiological pH (7.4), consequently decreasing the irritation to the eye. Moreover, increaseing the fraction of the unionized drug leads to enhancing the permeability of the drug through the cornea. The stability constant was determined from phase-solubility diagrams and found to be higher with KF/HP-ß-CD complex (29.47 M−1) than KF/ß-CD complex (10.36 M−1). Differential scanning calorimetry (DSC), fourier transforminfrared (FT-IR) spectroscopy and X-ray analysis (X-ray) showed the formation and the physiochemical proporties of the complex. The effect of different additives including; antioxidants, isotonicity adjusting agents and preservatives on the stability of ketotifen fumerate solution were studied. Sodium ascorbate (0.1%w/v) showed a significant increase in the stability of the KF solutoion. Fluid thioglycolate medium and Tryptic Soy Broth were used as a medium to test of sterility of selected formulations to detect aerobic, anaerobic and fungal contamination and verified that no turbidity or surface growth was observed during the incubation period of all tested formulae. Finally, the chemical stability using the stability indicating HPLC assay showed that the stability of the selected formulation were significantly higher in comparison to that of a commercial product (Zaditen® eye drops Novartis Pharma-Egypt) (p>0.05). These results indicate that KF/HP-ß-CD eye drops formulation is a promising (formulation) resulting in enhancing the solability, stability and permeability of the drug.
References
Kawakami S. et al, Controlled release and
ocular absorption of tilisolol utilizing
ophthalmic insert-incorporated lipophilic
prodrugs. J Control Release,
;76(3):255-63.
Klang S, Abdulrazik M and Benita S.
Influence of emulsion droplet surface
charge on indomethacin ocular tissue
distribution. Pharm Dev Technol,
;5(4):521-32.
Mezei MAM, Biopharmaceutics D. of
Ocular Drug Delivery, Edman P Editor.
CRC press, Boca Roton, Florida.
;91-104.
Hecht G, Remington. The Science and
Practice of Pharmacy. 19th ed. Gennaro
AR.Vol. II. Mack Publishing Company,
Easton, Pennsylvania, USA.
;610:563-1576.
Grant SM, et al., Ketotifen. A review of
its pharmacodynamic and
pharmacokinetic properties, and
therapeutic use in asthma and allergic
disorders. Drugs, 1990;40(3):412-48.
Uekama K, Hirayama F, and Irie T.
Cyclodextrin Drug Carrier Systems.
Chem Rev, 1998;98(5):2045-2076.
Loftsson T, Duchˆene D, Cyclodextrins
and their pharmaceutical applications. Int.
Pharm J. 2007;329:1–11.
Loftssona T, and Jarvinen T,
Cyclodextrins in ophthalmic drug
delivery. Adv Drug Deliv Rev,
;36(1):59-79.
Aktas Y, Unlu N, orhan M, Irkec M, and
Hincal AA. Influence of hydroxypropyl
beta-cyclodextrin on the corneal
permeation of pilocarpine. Drug Dev. Ind.
Pharm, 2003;29:223-230.
McDaid DM and Deasy PB. An
investigation into the transdermal delivery
of nifedipine. Pharm Acta Helv,
;71(4):253-8.
Higuchi T, Connors KA. Phase-solubility
techniques .Anal. Chem., 1965;4:117–
Loftsson T, Hreind ´ottir D M´, asson M.
The complexation efficiency. J. Incl.
Phenom. Macrocycl. Chem, 2007;57:545–
Kurozumi M, Nambu N and Nagai T.
Inclusion compounds of non-steroidal
antiinflammatory and other slightly water
soluble drugs with alpha- and betacyclodextrins in powdered form. Chem
Pharm Bull (Tokyo), 1975;23(12):3062-8.
Raymond CR, Wen SP SC. Handbook of
Pharmaceutical Excipients. 2003, London:
Pharmaceutical Press.
Patton TF and Robinson JR. Ocular
evaluation of polyvinyl alcohol vehicle in
rabbits. J Pharm Sci, 1975;64(8):1312-6.
Chiang CH, Chen JL, Liu YT. Therabutic
effectband pharmacokineticsof ketotifen
trans dermal delivary system. Drug Dev.
Indust. Pharm., 1998;24:213-217.
Carstensen J, in, Drug Stability3ed. Vol.
2000: Marcel Dekker, Inc., New
York , .
Del Valle, EMM, Cyclodextrins and their
uses .a review. ProcessBiochemistry,
;39:1033-1046.
Diaz D, et al. Complexation and solubility
behavior of albendazole with some
cyclodextrins. Pharm Dev Technol,
;3(3):395-403.
Botha SAAL AP, Compatibility studies
between isosorbide mononitrate and
selected excipients used in the
development of extended release
formulations. Drug Dev Ind Pharm,
;16(4):673.
Liu L and Zhu S Preparation and
characterization of inclusion complexes of
prazosin hydrochloride with betacyclodextrin and hydroxypropyl-betacyclodextrin. J Pharm Biomed Anal,
;40(1):122-7.
Ribeiro LSS, Ferreira DC and Veiga FJB,
Physicochemical investigation of the
effects of water-soluble polymers on
vinpocetine complexation with β-
cyclodextirn and its sulfobytyl ether
derivative in solution and solid state. .
Eur. J. Pharm. Sci. , 2003;20(3):253-266.
Jun SW, Kim MS, Kim JS, Park HJ, Lee
S, Woo JS and Hwang SJ. Preparation
and characterization of
simvastatin/hydroxypropyl-β-cyclodextrin
inclusion complex using supercritical
antisolvent (SAS) process. . Eur. J.
Pharm. Biopharm, 2007;66(3):413-421 .
Fernandes CM, Teresa VM and Veiga FJ.
Physicochemical characterization and in
vitro dissolution behavior of nicardipinecyclodextrins inclusion compounds. Eur.
J. Pharm. Sci., 2002;15(1):79-88.
Ficarra R, et al. Study of the inclusion
complex of atenolol with betacyclodextrins. J Pharm Biomed Anal,
;23(1):231-6.
Bayomi MA, Abanumay KA, and AlAngary AA. Effect of inclusion
complexation with cyclodextrins on
photostability of nifedipine in solid state.
Int J Pharm, 2002;243(1-2):107-17.
Abd El-Bary AA, E-G AN and Al-Gendy
NAH. Formulation and Evaluation of
Ciprofloxacin Hydrochloride Eye drops.
J. Biomed. Sci. , 2005;19:37-57.
The Pharmacopoeia of the United States
of America 27, The National Formulary
Asian Edition, Pharmacopoeial
Convention, In., Rockville, MD, U.S . ,
;454-458.
